country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N10949

Copy Link Print Information

Viscosalactone B

Viscosalactone B is an orally active LSD1 inhibitor with an IC₅₀ of 970.27 nM. Viscosalactone B targets COX-2, inhibits cyclooxygenase activity, and inhibits p97 ATPase activity in a cysteine-dependent manner. Viscosalactone B can be used in cancer-related research such as prostate cancer, lung cancer, and breast cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 76938-46-0
Formule: C₂₈H₄₀O₇
Masse moléculaire:488.61

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (290 KB)

Viscosalactone B Chemical Structure

CAS No.: 76938-46-0

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Références
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]^[6]

LSD1

970.27 nM (IC₅₀)

COX-2

p97 ATPase

Voir tous les produits spécifiques à Isoform COX :

Cellular Effect

Cell Line	Type	Value	Description	References
PC-3	IC50	1.17 μM	Antiproliferative activity against human PC3 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay. Antiproliferative activity against human PC3 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.	36692618
DU-145	IC50	0.72 μM	Antiproliferative activity against human DU145 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay. Antiproliferative activity against human DU145 prostate cancer cells assessed as viability reduction incubated 72 hrs by TBT assay.	36692618
NCI-H460	IC50	0.32 μg/mL	Antiproliferative activity against human NCI-H460 lung tumor cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human NCI-H460 lung tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.	14575818
HCT-116	IC50	0.47 μg/mL	Antiproliferative activity against human HCT-116 colon tumor cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human HCT-116 colon tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.	14575818
SF-268	IC50	0.45 μg/mL	Antiproliferative activity against human SF-268 CNS tumor cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human SF-268 CNS tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.	14575818
MCF7	IC50	0.40 μg/mL	Antiproliferative activity against human MCF-7 breast tumor cells assessed as viability reduction incubated 48 hrs by MTT assay. Antiproliferative activity against human MCF-7 breast tumor cells assessed as viability reduction incubated 48 hrs by MTT assay.	14575818

In Vitro

Anti-cancerInnate ImmunityLipid Inflammatory MediatorsOthers

Anti-cancer

Viscosalactone B (0.5-4 µM; 72 h) inhibits the proliferation of PC3, DU145, C42B, PC3/MDVR, DU145/MDVR, and C42B/MDVR prostate cancer cells, with the strongest effect on DU145 cells, with an IC₅₀ of 0.72 µM^[2].
Viscosalactone B (0.25-32 µM; 72 h) inhibits DU145 cell proliferation partly through inhibiting LSD1, with an IC₅₀ of 0.81 µM in DU145&shControl cells and 4.12 µM in DU145&shLSD1 cells^[2].
Viscosalactone B (0.3-0.9 µM; 48 h) increases the levels of H3K9me1, H3K9me2, and H3K4me1 in DU145 cells in a concentration-dependent manner^[2].
Viscosalactone B (compound 12) (48 h) inhibits the proliferation of NCI-H460, HCT-116, SF-268, and MCF-7 human tumor cell lines, with IC₅₀ values of 0.32, 0.47, 0.45, and 0.40 µg/mL, respectively^[4].

Innate Immunity

Lipid Inflammatory Mediators

Viscosalactone B (compound 8) (100-500 mg/mL; 2-3 min) selectively inhibits COX-2 by 35% at 100 mg/mL and shows no inhibition of COX-1 at 500 mg/mL in a cell-free COX assay using ram seminal vesicle COX-1 and insect cell-expressed human PGHS-2 COX-2^[3].

Others

Viscosalactone B selectively inhibits LSD1 in a cell-free enzymatic assay with an IC₅₀ of 970.27 nM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

DU145&shLSD1 and DU145&shControl prostate cancer cell lines
Concentration:

0.25, 0.5, 1, 2, 4, 8, 16, 32 µM
Incubation Time:

72 h (TBT assay)
Result:

LSD1 gene expression rates were 9.3% in DU145&shLSD1 cells and 99.7% in DU145&shControl cells.
Inhibited DU145&shControl cells with an IC₅₀ of 0.81 µM and DU145&shLSD1 cells with an IC₅₀ of 4.12 µM, approximately 5-fold less potent in LSD1-knockdown cells.

Western Blot Analysis^[2]

Cell Line:

DU145 prostate cancer cells
Concentration:

0.3, 0.6, 0.9 µM
Incubation Time:

48 h
Result:

Induced concentration-dependent accumulation of LSD1 substrates H3K9me1, H3K9me2, and H3K4me1 in DU145 cells.

In Vivo

Anti-cancer

Viscosalactone B (30 mg/kg; intragastric administration; 21 days) inhibits the growth of DU145 prostate cancer xenograft tumors in BALB/c nude mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude (18-25 g)^[2]
Dosage:

30 mg/kg
Administration:

intragastric (i.g.); for 21 days
Result:

At 30 mg/kg, DU145 tumor growth was suppressed.
At 30 mg/kg, tumor weight was inhibited in BALB/c nude mice.

Related Protocols :

Breast Cancer Modeling

Chemical Information

CAS No. 76938-46-0
Masse moléculaire 488.61
Formule C₂₈H₄₀O₇
SMILES

C[C@]12[C@@]3([C@H]([C@H](CC2=O)O)O)[C@](C[C@]4([H])[C@]1([H])CC[C@]5([C@@]4([H])CC[C@]5([H])[C@@H]([C@@]6([H])CC(C)=C(C(O6)=O)CO)C)C)([H])O3
Structure Classification
- Steroids
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (290 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Khairy A, et al. Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach. Scientific reports. 2022 Nov 09;12(1):19037.

[2]. Yan G, et al. Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells. Invest New Drugs. 2023 Feb;41(1):134-141.

[3]. Jayaprakasam B, et al. Cyclooxygenase-2 enzyme inhibitory withanolides from Withania somnifera leaves. Tetrahedron. 2003;59(6):841–849.

[4]. Jayaprakasam B, et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life sciences. 2003 Nov 21;74(1):125-32. [Content Brief]

[5]. Santagata S, et al. Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS chemical biology. 2012 Feb 17;7(2):340-9.

[6]. Tao S, et al. Withaferin A Analogs That Target the AAA+ Chaperone p97. ACS chemical biology. 2015 Aug 21;10(8):1916-1924.

Calculators

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis